CAMBRIDGE, Mass. — NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company’s investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS), on...
Latest News
CUMBERLAND, R.I. — Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the first commercial manufacturing, shipment, and surgical procedure for ENCELTOTM (revakinagene taroretcel-lwey), an encapsulated cell-based gene therapy and the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type...
PALO ALTO, Calif. — Neuvivo, Inc., a late-stage biopharmaceutical company developing treatments for neurodegenerative disease, today announced it has gained alignment with the U.S. Food and Drug Administration (FDA) on a regulatory path forward for NP001 as a unique immunotherapy to treat amyotrophic lateral sclerosis (ALS). This follows a Type...
Toronto, Canada – Researchers at The Hospital for Sick Children (SickKids) have found that inflammation in an immune cell may be responsible in part for some severe symptoms in a group of rare genetic conditions called lysosomal storage diseases (LSDs). LSDs affect about one in 7,700 live births worldwide. Children...
TORONTO, Canada – A new round of clinical trials supported by the Ontario Institute for Cancer Research (OICR) will harness a unique opportunity to test some of the newest treatment strategies for a range of different cancers. OICR has announced two new clinical trials as part of its Window-of-Opportunity (WOO)...
SOUTH SAN FRANCISCO, Calif. – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular...
COPENHAGEN, Denmark — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea...
New Rochelle, NY – Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis (CF) in the peer-reviewed journal Human Gene Therapy. They also showed that after single dose inhaled delivery of SP-101, SP-101 vector genomes were detected throughout the respiratory tract...
Barcelona, Spain – Researchers at the Centre for Genomic Regulation (CRG), the University of the Basque Country (UPV/EHU), Donostia International Physics Center (DIPC) and the Fundación Biofisica Bizkaia (FBB, located in Biofisika Institute) have developed an artificial intelligence which can differentiate cancer cells from normal cells, as well as detect...
Ridgefield, Connecticut – Boehringer Ingelheim announced new analyses to be presented at the American Academy of Dermatology (AAD) annual meeting in Orlando that explore the effect that SPEVIGO® (spesolimab-sbzo) may have on the physical symptoms and mental health burden associated with generalized pustular psoriasis (GPP). These post-hoc exploratory analyses from the...